Skip to main content
. 2017 Sep 18;8(49):86130–86142. doi: 10.18632/oncotarget.20991

Figure 3. Pathological and oncological outcomes.

Figure 3

The number of pT0 and pT3-4 patients was significantly higher and lower in the NAC group than the Ctrl group, respectively (A). In addition, pathological T0 was achieved in 23% of patients. There were significant differences in progression-free (B) and overall survival (C) measures between the Ctrl and NAC groups. No statistical difference was observed between groups in progression-free (D) and overall survival (E) in the patients with stage 3 CKD.